amplidex pcr ce c9orf72 kit amplidex asr gpr reagents oncology quantidex qpcr bcr abl is kit quantidex qpcr dna qc assay quantidex ngs pan cancer kit custom & companion diagnostics commercialization product approval development discovery partnered r & d tumor bank partnered r & d cap accredited clia lab cta testing site validated platforms & assays tumor bank custom reagents armored reagents in vitro transcribed rna plasmid dna companion diagnostics commercialization product approval development discovery partnered r & d tumor bank partner with us enabling technologies assay chemistries bioinformatics product development process resources videos publications technical documents fragile x leukemia sales contacts community community events spotlight sales contacts about leadership team culture and heritage press releases upcoming events business development contact careers search it s more than a result . it s a person . we re driven to know . genetics icon genetics innovative solutions that empower researchers from als to fragile x syndrome . learn more about our genetics portfolio oncology icon oncology solving complex molecular challenges from leukemia to solid tumors . learn more about our oncology portfolio cdx icon custom & companion diagnostics one partner from clinical concept to product commercialization . learn more about partnering with us . spotlight go deep with the first and only fda cleared bcr abl1 assay we are pleased to announce that we have received fda clearance through the de novo 510 k process for our quantidex qpcr bcr abl is kit for monitoring molecular response in chronic myeloid leukemia patients . learn more spotlight accurate c9orf72 analysis just got easier introducing amplidex pcr ce c9orf72 kit ruo for high resolution genotyping of gc rich hexanucleotide repeat expansions in the c9orf72 gene that are associated with als and ftd . learn more spotlight ngs rna lung cancer kit coming soon we are pleased to introduce our next ngs solution within the quantidex oncology line of assays quantidex ngs rna lung cancer kit ruo . learn more spotlight asuragen develops armored rna quant zika virus control we are committed to leveraging our armored rna technologies to develop high quality controls in response to emerging viral threats such as ebola in 2015 and now for zika . read more the latest from asuragen introducing the first and only fda cleared bcr abl1 assay we are pleased to announce that we have received fda clearance through the de novo 510 k process for our quantidex qpcr bcr abl is kit for monitoring molecular response in chronic myeloid leukemia patients . press release asuragen develops armored rna quant zika virus control event sep 28 national society of genetic counselors nsgc annual education conference seattle wa national society of genetic counselors nsgc annual education conference seattle wa sep 28 2016 oct 1 2016 the aec focuses specifically on the educational needs of genetic counselors and addresses a wide variety of genetic counseling practice areas and provides the latest information for the genetic counseling profession . attendees will gain important information to support and enhance their current practice . visit event website press release asuragen s quantidex qpcr bcr abl is kit receives fda premarket clearance for monitoring minimal residual disease in chronic myeloid leukemia press release asuragen launches the amplidex pcr ce c9orf72 kit for high resolution genotyping of gc rich repeat expansions relevant to amyotrophic lateral sclerosis and frontotemporal dementia back totop asuragen inc. 2150 woodward st. suite 100 austin tx 78744 usa portfolio custom & companion diagnostics enabling technologies resources community about contact careers copyright 2016 asuragen inc. an equal opportunity employer . all rights reserved . privacy policy website terms of use by continuing to use the site you agree to the use of cookies . more information accept the cookie settings on this website are set to allow cookies to give you the best browsing experience possible . if you continue to use this website without changing your cookie settings or you click accept below then you are consenting to this . close